From gut dysbiosis to synaptic dysfunction in insomnia-associated depression: immune mechanisms and nutritional interventions.
Frontiers in immunology · 2026
Abstract originale
Insomnia and depression frequently coexist, yet their shared biological mechanisms have not been systematically integrated, limiting the development of targeted preventive and therapeutic strategies. Growing evidence identifies immune dysregulation as a key link between insomnia and depression, with the microbiota-gut-brain axis providing an important mechanistic framework. This review summarizes how insomnia induced gut microbiota alterations disrupt intestinal homeostasis, promote peripheral and central inflammation, and impair synaptic function during depression. It also discusses dietary interventions, food derived bioactive compounds, probiotics, and other microbiota targeted strategies. Targeting microbiota mediated immune pathways may provide new opportunities for the prevention and treatment of insomnia related depression.
Parole chiave
Leggi il testo integrale originale
Testo estratto dalla pubblicazione: sono esclusi immagini, media, supplementi e parti soggette a diritti distinti.
From gut dysbiosis to synaptic dysfunction in insomnia-associated depression: immune mechanisms and nutritional interventions
Abstract
Insomnia and depression frequently coexist, yet their shared biological mechanisms have not been systematically integrated, limiting the development of targeted preventive and therapeutic strategies. Growing evidence identifies immune dysregulation as a key link between insomnia and depression, with the microbiota-gut-brain axis providing an important mechanistic framework. This review summarizes how insomnia induced gut microbiota alterations disrupt intestinal homeostasis, promote peripheral and central inflammation, and impair synaptic function during depression. It also discusses dietary interventions, food derived bioactive compounds, probiotics, and other microbiota targeted strategies. Targeting microbiota mediated immune pathways may provide new opportunities for the prevention and treatment of insomnia related depression.
Keywords: depression, immune inflammation, insomnia, microbiota dysbiosis, microbiota-gut-brain axis, personalization, probiotics, synaptic plasticity
Graphical Abstract
Gut microbiota dysbiosis associated with insomnia may contribute to immune dysregulation and depression. Interventions targeting the gut microbiota may help restore homeostasis between the gut and brain and alleviate depression associated with insomnia.
Infographic illustrating the connection between insomnia, depression, and the gut-brain axis, and how dietary interventions—probiotics, prebiotics, plant polysaccharides, dietary fiber, and herbs—can help restore healthy gut microbiota and improve emotional regulation.
1.Introduction
Insomnia is one of the most common sleep-related disorders, with insomnia symptoms affecting approximately 35-50% of adults worldwide, although these estimates generally refer to symptoms rather than clinically diagnosed insomnia disorder (1–3). A prevalence of 64.6% has been reported in a specific population of Chinese adults based on questionnaire-defined sleep disturbances, rather than physician-diagnosed insomnia disorder, highlighting the substantial burden of sleep problems while requiring careful interpretation across different populations and diagnostic criteria (4). Depression is a highly disabling psychiatric disorder that affects hundreds of millions of people worldwide and imposes a substantial personal, social, and economic burden (5). Importantly, insomnia and depression frequently coexist, with insomnia symptoms observed in a large proportion of individuals with depression, and increasing evidence suggesting that insomnia represents not only a symptom but also an independent risk factor for depressive onset and recurrence (6–8).
Current mechanistic and therapeutic research on insomnia and depression has largely focused on circadian rhythm disruption, including interventions such as light therapy, melatonin administration, and chronotherapy (9). However, accumulating evidence indicates that the biological interaction between these disorders involves multiple interconnected systems beyond circadian regulation. Among these, the microbiota–gut–brain axis has emerged as an important framework linking sleep disturbance, immune dysfunction, and neuropsychiatric disorders. The gut microbiota communicates bidirectionally with the central nervous system through microbial metabolites, immune signaling, neuroendocrine pathways, and neural routes, forming the microbiota-gut-brain axis (10). Dietary factors and food-derived bioactive compounds can further influence this network by modifying microbial composition, metabolite profiles, intestinal barrier function, and host immune responses.
Altered gut microbial composition has been reported in both insomnia and depression, although microbial signatures specific to their comorbidity remain incompletely characterized. Emerging evidence suggests that insomnia-associated gut dysbiosis may impair intestinal barrier integrity, promote peripheral and central inflammatory activation, and contribute to neuronal dysfunction and impaired synaptic plasticity (11). Nevertheless, the mechanisms linking microbiota-mediated immune alterations with depressive phenotypes remain insufficiently integrated, particularly from the perspective of nutritional regulation and microbiota-targeted intervention.
Previous reviews have addressed the microbiome in relation to insomnia, depression, and related neurobiological mechanisms (12, 13). Building on this work, the present review focuses specifically on depression associated with insomnia and integrates the pathological continuum from gut microbial dysregulation and intestinal barrier dysfunction to immune activation, neuroinflammation, and impaired synaptic plasticity within a microbiota immune synapse framework. We further examine dietary interventions, food derived bioactive compounds, probiotics, and other microbiota and immune targeted strategies, while distinguishing their supporting levels of evidence and translational relevance. This integrated perspective aims to provide a comprehensive basis for understanding the pathophysiology of insomnia associated depression and for identifying potential nutritional and therapeutic approaches.
2.Gut microbiota brain axis in the context of insomnia-associated depression
The balance of gut microbiota is closely linked to human health, and its association with depression has emerged as a promising target in mental health interventions (14). Insomnia, a common sleep disorder, may disrupt gut microbial homeostasis through the bidirectional microbiota-gut-brain axis, thereby influencing overall health (15). Sleep disturbances and gut dysbiosis exhibit a bidirectional relationship: sleep deprivation perturbs gut microbiota composition and metabolism (16), The relationship between sleep disturbances and gut dysbiosis is bidirectional: sleep deprivation alters the composition and function of gut microbiota, while microbial imbalance may in turn impair sleep quality. These findings suggest that gut dysbiosis may be a key contributor to sleep disorders (17). Advances in microbiota-gut-brain axis research have highlighted microbiota-targeted functional compensatory therapeutics, including probiotics, prebiotics, small molecules, plant polysaccharides, and synthetic biology-engineered microbes (18). The relationship between the microbiota and insomnia-associated depression is shown in Figure 1. By enhancing beneficial taxa and preserving microbial homeostasis, these strategies promote host health with reduced adverse effects and improved adherence.
2.1.Constituents of the gut microbiota brain axis and their relevance to insomnia-associated depression
The microbiota-gut-brain axis exerts its effects primarily through the vagus nerve, endocrine system, immune system, and metabolic pathways (11). The vagus nerve, the longest cranial nerve connecting the peripheral and central nervous systems, serves as a critical conduit for signal transmission and physiological regulation within this axis (19). Emerging evidence indicates that gut microbiota can produce neurotransmitters such as acetylcholine and dopamine, which influence emotional, behavioral, and cognitive functions via vagal signaling (20). The microbiota-gut-brain axis also involves endocrine pathways, notably the HPA axis (21).
Gut microbiota can modulate host stress responses by influencing HPA axis activity. As a central hub of gut-brain communication, the HPA axis is initiated by the release of corticotropin-releasing hormone (CRH) from the paraventricular nucleus of the hypothalamus (22), which stimulates the pituitary to secrete adrenocorticotropic hormone (ACTH), subsequently promoting cortisol production by the adrenal cortex. Cortisol then exerts negative feedback on both CRH and ACTH to maintain homeostasis. Notably, the secretion of these hormones is regulated by circadian rhythms and occurs in parallel with gut microbiota development (23). Immune signaling, particularly cytokine-mediated pathways, represents another key mechanism through which the microbiota-gut-brain axis influences the central nervous system. Gut microbiota modulates neuroimmune communication by producing short-chain fatty acids (SCFAs), lipopolysaccharides (LPS), and pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α. These mediators can affect Blood-Brain Barrier (BBB) permeability, alter vagal nerve signaling, and modulate HPA axis activity, thereby impacting central nervous system function (24). The following is the corresponding logical mechanism pathway Figure 2.
2.2.Alterations in gut microbiota composition and function in insomnia-associated depression
Insomnia markedly reduces the α-diversity of the gut microbiota, characterized by an imbalanced Firmicutes-to-Bacteroidetes ratio (25). This is accompanied by a decreased abundance of beneficial genera such as Faecalibacterium and Roseburia (26), alongside an increased relative abundance of opportunistic taxa including Prevotella and Blautia (27). Such compositional shifts primarily disrupt the tryptophan metabolic pathway, leading to reduced 5-hydroxytryptamine (5-HT, serotonin) synthesis and consequently impairing the microbiota-gut-brain axis in emotional regulation (28).
Insomnia is often accompanied by elevated cortisol levels, which, via glucocorticoid receptor (GR) activation, suppress the expression of key tight junction proteins ZO-1, occludin, and Claudin-1 in intestinal epithelial cells (29), thereby compromising gut barrier integrity and inducing a “leaky gut” phenotype (30). The resulting barrier disruption increases translocation of pathogen-associated molecular patterns (PAMPs), such as LPS, into the circulation, activating the TLR4/NF-κB inflammatory pathway (31). This, in turn, facilitates peripheral cytokines including IL-6, TNF-α, and IL-1β to penetrate the BBB, exacerbating microglial activation, impairing neuroplasticity, and ultimately contributing to depression onset. Therapeutic strategies aimed at reconstructing microbial metabolic pathways, restoring gut barrier function, and alleviating systemic inflammation hold promise for overcoming the single target limitations of conventional antidepressants (32). Targeting the “microbiota-immune-synapse” axis to achieve system level modulation represents a key direction in the development of next generation antidepressant interventions. The following is the corresponding logical mechanism pathway Figure 3. We have compiled clinical cases featuring the characteristics of gut microbiota imbalance in depression following insomnia, as shown in Table 1.
Table 1Microbial imbalance characteristics associated with insomnia and depression.
Subjects Type Function Depression Abnormal flora References
Human (n=24) Chronic insomnia SCFA production, immune regulation, anti-inflammation No ↓ Bacteroidaceae, ↓ Ruminococcaceae, ↓ Bacteroides, ↑ Prevotellaceae, ↑ Prevotella, ↑ Gemmiger, ↑ Fusicatenibacter (33)
Human (n=20 Acute, n=38 Chronic) Acute and Chronic insomnia SCFA production, anti-inflammation No Acute:↓ Lachnospira, ↓ Bacteroides, Chronic:↓ Faecalibacterium, ↓ Roseburia, ↑ Blautia, ↑ Eubacterium hallii (34)
Female mice Chronic Sleep deprivation SCFA production, anti-inflammatory, intestinal regulation Yes ↑ Rothia, ↑ Streptococcus, ↑ Pantoea, ↑ Klebsiella, ↓ Rikenella, ↓ Eubacterium xylanophilum group, ↓ Eisenbergiella (35)
Human (n=36) Chronic insomnia SCFA production, anti-inflammation Yes ↑ Dorea, ↑ Intestinibacter, ↓ Coprococcus (36)
Human (n=40) Chronic insomnia Promotes sleep, anti-inflammatory Yes ↑ Bacteroides, ↓ Bifidobacterium (37)
Human (n=20) Chronic insomnia SCFA production, anti-inflammatory, sleep promotion No ↑ Prevotella, ↑ Gemmiger, ↑ Fusicatenibacter, ↓ Bacteroides, ↓ Coprococcus, ↓ Oscillibacter, ↓ Clostridium XI (33)
Human (n=38) Chronic insomnia SCFA production, anti-inflammation No ↓ Faecalibacterium, ↓ Roseburia, ↑ Blautia (34)
Human (n=45) Chronic insomnia SCFA production, anti-inflammation Yes ↑ Dorea, ↑ Intestinibacter, ↓ Coprococcus (36)
Human (n=159) Sleep quality varying Microbial Community Structure and Sleep Quality Link Yes ↑ F. prausnitzii (38)
↑, increased abundance; ↓, decreased abundance.
2.3.Gut microbiota-mediated modulation of tryptophan metabolism in sleep disturbance-related depression
Tryptophan, an essential amino acid, plays a pivotal role in regulating sleep-wake rhythms. It is metabolized through multiple pathways to produce neuroactive compounds (39), primarily including 5-HT, kynurenine, and various indole derivatives (40). Among these, the 5-HT-melatonin pathway is most directly associated with sleep quality.
5-HT biosynthesis primarily depends on the activity of tryptophan hydroxylase isoforms TPH1 and TPH2, which catalyze the conversion of tryptophan into 5-hydroxytryptophan (5-HTP) (41). 5-HTP is then converted to 5-HT by aromatic L-amino acid decarboxylase (AADC), and subsequently transformed in the pineal gland into melatonin-an essential hormone for circadian rhythm regulation and sleep initiation (42). Studies indicate that in insomnia-associated depression, exacerbated neuroinflammation serves as an upstream driver that downregulates central TPH2 expression. This suppression consequently may leads to reduced 5-HT and melatonin levels, which further aggravates insomnia symptoms. Such biochemical shifts are closely linked to alterations in gut microbiota composition, particularly within the phylum Firmicutes (43).
Dysbiosis of the gut microbiota can alter tryptophan metabolism, thereby affecting the production and function of 5-HT. For instance, specific genera such as Lactobacillus and Bifidobacterium can upregulate TPH1 expression, enhancing 5-HT synthesis and exerting antidepressant effects (44, 45). Notably, gut microbiota composition, metabolic activity, and stress resilience vary considerably across individuals depending on age, sex, and environmental factors, which may explain the suboptimal efficacy of single-target interventions (46). Developing “microbiota function compensating” therapeutics based on the metabolism-transport-neuro regulation network, along with microbiome modulation through probiotics or dietary interventions, represents a promising strategy to alleviate insomnia, restore neurotransmitter homeostasis, and optimize sleep architecture. The following is the corresponding logical mechanism pathway Figure 4.
2.4.Role of gut-derived GABA in neurophysiology of insomnia-associated depression
γ-Aminobutyric acid is a key inhibitory neurotransmitter that regulates neuronal excitability, facilitating relaxation and the initiation of sleep (47). Recent studies indicate that the gut microbiota plays a crucial role in GABA metabolism, and targeting this metabolic cycle offers valuable insights into the pathophysiology and treatment of insomnia-associated depression (48). Genera such as Bacillus and Lactobacillus can produce GABA or activate GABA receptors to enhance sleep propensity. Patients with insomnia and depression often exhibit reduced GABA levels in the brain, along with structural impairments in α1, β2, and γ2 subunits of GABA receptors, leading to diminished inhibitory synaptic signaling and neuronal excitability (49). Restoring microbial balance to boost GABA biosynthetic enzymes, particularly glutamate decarboxylase (GAD) activity, may help ameliorate such neural damage. The regulatory relationship of the brain-gut axis is shown in Figure 5. Additionally, oral GABA supplementation and the development of delivery systems with improved bioavailability represent promising microbiota-gut-brain axis-based strategies for indirectly modulating central GABA pathways to alleviate insomnia-associated depression.
3.Immune axis imbalance in the pathogenesis of insomnia-associated depression
With growing research into the interplay between sleep and immunity, accumulating evidence reveals a complex bidirectional relationship between insomnia-associated depression and the immune system (50). This dynamic regulatory network is closely linked to multiple neurotransmitters, cytokines, and HPA axis activity (51). Immune imbalance may manifest as either immunosuppression or excessive inflammatory responses, depending on the duration and severity of insomnia, as well as individual variability.
Insomnia reduces the activity of natural killer cells, T cells, and phagocytes, thereby weakening host defense capacity (52). With compromised immune integrity, these cells become less efficient in detecting and eliminating pathogens, cancer cells, and damaged cells, increasing susceptibility to infections and disease. The immune system also interacts with the central nervous system (CNS) via pro-inflammatory signaling to influence melatonin secretion, thereby regulating the sleep and wake cycle (53). Under physiological conditions, IL-1 and TNF-α key mediators of innate immunity act as “sleep molecules” by modulating non-rapid eye movement (NREM) sleep and maintaining sleep quality (54). The following is the corresponding logical mechanism pathway Figure 6. In contrast, insomnia is often accompanied by excessive secretion of pro-inflammatory cytokines, driving chronic neuroinflammation and contributing to the pathogenesis of multiple disorders, including cardiovascular disease, diabetes, and neurodegenerative conditions (55).
3.1.The association between insomnia-induced inflammatory cytokine storms and depression
As described above in Section 2.2, stress-induced HPA-axis activation and elevated cortisol may impair intestinal barrier integrity, facilitating microbial product translocation and subsequent immune activation. This process involves TLR4/NF-κB signaling, inflammatory cytokine release, and downstream effects on BBB integrity and microglial activation. The imbalance of inflammatory factors also promotes activation of the NOD-like receptor protein 3 (NLRP3) inflammasome, inducing neuronal apoptosis and impairing synaptic function (56). Moreover, pro-inflammatory cytokines TNF-α and IL-1β suppress the expression of brain-derived neurotrophic factor (BDNF), postsynaptic density protein 95 (PSD-95) (57), and synaptophysin by activating the MAPK signaling pathway, resulting in reduced synaptic plasticity and consequently leading to cognitive and emotional disorders (58). Developing targeted therapies that stabilize immune function and regulate inflammation following insomnia is a critical strategy for treating depression caused by chronic sleep disturbances.
3.2.The role of prostaglandin D2 as a bridge between sleep and immunity
Prostaglandin D2 (PGD2), a metabolite of arachidonic acid, has been proposed as a mediator linking sleep regulation and peripheral immune responses (59). Under sleep deprivation, increased activity of lipocalin-type prostaglandin D synthase (L-PGDS) in the meninges and glial cells leads to a significant elevation of PGD2 levels (60). Transported across the BBB into the peripheral circulation via MRP4, PGD2 disrupts peripheral immune homeostasis. However, the proposed PGD2-mediated inflammatory pathway is supported primarily by mechanistic and animal studies, and its relevance to human insomnia-associated depression remains to be established.
In the periphery, PGD2 binds to the high-affinity receptor GPR44, activating the Gs protein and stimulating adenylyl cyclase to produce cAMP (61). This cascade further activates protein kinase A (PKA) and the CREB pathway, regulating the expression of immune cell functional genes. Neutrophils, eosinophils, and Th2 cells are notably activated, promoting their migration to peripheral tissues and releasing pro-inflammatory cytokines such as IL-4, IL-5, IL-13, and TNF-α, thereby exacerbating immune imbalance (62). Studies have shown that specific antagonism of the DP1 receptor or inhibition of PGD2 synthase expression effectively suppresses neutrophil migration and reduces peripheral inflammatory cytokines, reversing sleep deprivation-induced systemic immune activation and alleviating depression-related symptoms (63). The key immune factor regulatory mechanism of insomnia-associated depression is shown in Figure 7.
3.3.Persistent HPA axis activation in insomnia-induced depression
The sustained activation of the HPA axis is considered a central neuro-immune-endocrine pathway in the pathogenesis of insomnia-induced depression (64). Chronic stress from insomnia stimulates the excitability of CRH neurons in the paraventricular nucleus (PVN) of the hypothalamus (65), leading to increased synthesis and secretion of CRH. CRH acts on CRHR1 receptors in the anterior pituitary, activating the adenylyl cyclase (AC)/cAMP/PKA signaling pathway, resulting in elevated cortisol levels (66). Under sustained HPA axis hyperactivation, high cortisol concentrations suppress transcription of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α, inhibit T cell proliferation, Th1 cell activation, and IFN-γ expression, while promoting a shift toward Treg and Th2 cells (67). This shift weakens cellular immune responses and impairs antigen clearance capacity.
Chronic insomnia may also lead to glucocorticoid receptor overload and the development of glucocorticoid resistance (68), weakening the negative feedback regulation on inflammatory responses (69). This results in sustained elevation of IL-6 and TNF-α, establishing a chronic low-grade inflammatory state that suppresses the expression of BDNF within the central nervous system (70). Ultimately, this cascade contributes to the development of a depressive phenotype characterized by mood disturbances and cognitive impairment. Representative pharmacological agents targeting immune pathways and the HPA axis are summarized in Table 2, together with their levels of evidence and potential relevance to depression associated with insomnia.
Table 2Targeted drugs that improve insomnia-associated depression by regulating immunity.
Drug name Effect Target Key pathways Dosage Evidence level Reference
Asapiprant Asthma, allergic rhinitis, inflammation PGD2 receptors PGD2-DP1/DP2 axis, cytokine response 100 mg/day PE (71)
Prednisone Inflammation, autoimmune diseases Glucocorticoid receptor HPA axis, T cell and cytokine suppression 5–60 mg/day OHE (72)
Fluoxetine Depression 5-HT reuptake inhibition, HPA axis HPA axis modulation via serotonergic 20–80 mg/day PE (73)
Ketoconazole Fungal infections, endocrine disorders Cytochrome P450 enzymes, steroidogenesis Steroid biosynthesis inhibition, HPA axis 200–400 mg/day OHE (74)
DHEA Endocrine dysfunction Glucocorticoid, androgen receptors Steroid hormone modulation, neuroimmune balance 25–100 mg/day OHE (75)
Ibuprofen Pain and inflammation Cyclooxygenase (COX) COX-PGE2, neuroinflammation 200–400 mg every 4–6 h PE (76)
Loratadine Allergic diseases Histamine H1 receptor antagonist Allergic inflammation, histamine 10 mg/day OHE (77)
Cyclosporine Autoimmune diseases Calcineurin inhibition T cell signaling, NFAT 2.5–5 mg/kg/day PE (78)
Infliximab Ankylosing spondylitis, depression, anxiety TNF-α TNF-α-mediated inflammatory signaling 5 mg/kg every 8 weeks OHE (79)
Tocilizumab Inflammatory diseases IL-6 receptor blockade IL-6-JAK-STAT3 8 mg/kg every 4 weeks OHE (80)
Thalidomide Multiple myeloma, lymphoma Cereblon modulation TNF-α and CRBN-mediated immune modulation 10 mg/day PE (81)
PE, preclinical evidence; OHE, observational human evidence; RCE, randomized clinical evidence; H/PM, hypothesis or proposed mechanism.
4.Synaptic axis: central role in neural communication and emotional stability
The synaptic axis, as a central regulator of neuronal communication, emotional stability, and cognitive function, relies heavily on the integrity of synaptic structure and the dynamic regulation of synaptic plasticity (82).
Studies have shown that chronic sleep deprivation significantly impairs synaptic plasticity, primarily long-term potentiation (LTP), especially in emotion-regulating brain regions such as the hippocampal CA1 area, prefrontal cortex, and amygdala (83). This impairment is mainly associated with a marked downregulation of BDNF expression and limited activation of its receptor TrkB signaling axis (84). Additionally, excessive release of the excitatory neurotransmitter glutamate induces intracellular Ca2+ overload, causing excitotoxicity that ultimately leads to synaptic damage and neuronal apoptosis (85). Moreover, insomnia weakens GABAergic function by downregulating GABA receptor subunits (α1, β2, γ2), resulting in overall neural network hyperexcitability and disrupted neuronal firing patterns, which contribute to anxiety and depressive behaviors (86).
4.1.The mechanism of insomnia’s damage to synaptic plasticity
Synaptic plasticity is a fundamental physiological process essential for maintaining emotional stability and cognitive function, and it is closely linked to sleep quality and states. Synaptic plasticity encompasses three main aspects: modulation of synaptic strength, reversible regulation of synaptic structure, and synaptic function (87). Key processes involved include LTP, long-term depression (LTD), dendritic spine remodeling, and post-synaptic receptor activity (88). Slow-wave sleep (SWS) and rapid eye movement (REM) sleep represent critical temporal windows for synaptic plasticity, primarily consolidating synaptic stability to enhance neural network information processing efficiency and emotional regulation (89).
Studies have shown that in chronic sleep restriction (CSR) animal models, there is a significant downregulation of PSD-95 expression, thinning of the postsynaptic density, and a reduction in dendritic spine density. Additionally, key synaptic receptors such as GluA1 and NR2B are suppressed (90). These synaptic alterations mirror the deficits observed in depression models induced by chronic unpredictable mild stress (CUMS), suggesting a close link between insomnia-induced synaptic damage and the pathogenesis of depression (91). Prolonged sleep deprivation enhances glutamate excitotoxicity, causing excessive Ca2+ influx through NMDA receptors, which activates caspase cascades leading to reactive oxygen species (ROS) production and oxidative damage to synaptic structures (92). Concurrently, impaired GABA function reduces inhibitory synapses, disrupting the excitation-inhibition balance within neural networks and exacerbating depressive symptoms (93). Therefore, given that sleep is essential for maintaining synaptic plasticity, future therapeutic strategies targeting insomnia-associated depression should focus on restoring synaptic homeostasis and functional consolidation by regulating synaptic protein synthesis, receptor trafficking, dendritic spine remodeling, and neurotrophic factor signaling. The relationship between insomnia-associated depression and synaptic axes is shown in Figure 8.
4.2.The potential application of synaptic plasticity in the treatment of insomnia and depression
Synaptic plasticity restoration has emerged as a central therapeutic strategy and has been extensively investigate. Traditional antidepressants, such as selective 5-HT reuptake inhibitors (SSRIs) and 5-HT-norepinephrine reuptake inhibitors (SNRIs) (94), exert their effects by inhibiting the reuptake of 5-HT and norepinephrine, thereby increasing neurotransmitter concentrations within the synaptic cleft and enhancing neuronal communication (95).
Reports indicate that SSRIs can activate the cAMP/PKA/CREB signaling pathway to upregulate BDNF expression, thereby promoting synaptogenesis and stabilization, and restoring synaptic structure and functional plasticity (96). Targeted drugs aimed at repairing synaptic plasticity show promising therapeutic potential. For instance, the natural compound kaempferol (KMP) has been found to inhibit microglial activation and inflammatory cytokine release, improving hippocampal synaptic architecture and behavioral phenotypes, suggesting an antidepressant effect via an “anti-inflammatory and pro-plasticity” mechanism (97). Traditional Chinese medicine formulas like Tianwang Buxin Pill exert antidepressant effects through sleep promotion, calming the mind, and liver soothing (98).
Non-pharmacological interventions, such as aerobic exercise, also demonstrate clear benefits in enhancing sleep quality and alleviating depressive symptoms. Exercise upregulates hippocampal BDNF protein expression, fostering synaptogenesis and enhancing central signal processing efficiency (99). Moreover, electroacupuncture therapy (4), validated in both clinical and animal studies (100), improves postsynaptic signal transmission and promotes synaptic structural remodeling by upregulating key proteins including NMDAR and PSD-95, thereby improving sleep quality and emotional disturbances (101). Future research integrating neuroimaging, multi-omics, and behavioral assessments aims to elucidate the precise regulatory mechanisms of various interventions on synaptic plasticity, facilitating their translational application in the prevention and treatment of insomnia-associated depression.
5.Current status of antidepressant uses and treatment differences for comorbid insomnia
Pharmacological interventions remain the first-line treatment for insomnia-induced depression. However, their long-term efficacy and safety are hindered by several challenges, including frequent adverse effects, development of tolerance, poor patient adherence, and substantial interindividual variability in therapeutic response (102). Currently, antidepressants remain the most commonly prescribed pharmacological agents for treating insomnia-associated depression, primarily including selective SSRIs, SNRIs, mirtazapine, and bupropion (103). Although these agents demonstrate clear efficacy in alleviating depressive symptoms, their effects on comorbid insomnia vary considerably.
Studies indicate that SSRIs may prolong sleep onset latency, reduce total sleep time, and even exacerbate insomnia symptoms. In contrast, mirtazapine and bupropion, due to their sedative properties (104), demonstrate certain advantages in improving sleep quality. However, their use warrants caution because of potential adverse effects such as weight gain, metabolic disturbances, and sexual dysfunction (105). In clinical practice, antidepressants are not routinely employed as first-line treatment for acute insomnia; they are considered alternative options primarily when cognitive behavioral therapy for insomnia (CBT-I) or conventional sedative-hypnotics prove ineffective (106). Therefore, antidepressants are generally utilized as adjunctive or second-line therapies in insomnia management rather than as primary treatment choices.
6.Therapeutic interventions for insomnia-associated depression and translational challenges
Adherence issues represent a common barrier in long-term antidepressant therapy, with patients frequently discontinuing medication prematurely due to delayed onset of therapeutic effects (107). Concurrently, adverse effects such as nausea, dry mouth, constipation, and weight gain can further diminish patient satisfaction and adherence (108). Significant interindividual variability in genetic background, drug metabolism capacity, and clinical phenotypes contributes to pronounced heterogeneity in treatment response to the same medication among different patients.
A subset of patients experiences significant therapeutic benefits, whereas others may exhibit suboptimal efficacy or pronounced adverse effects (109). This individualized variability markedly increases the complexity and resource demands of formulating precise clinical treatment strategies. Furthermore, depression patients often present with multiple comorbid somatic conditions requiring polypharmacy, which heightens the risk of drug-drug interactions that can both attenuate therapeutic efficacy and exacerbate adverse reactions (110). Pharmacological treatment planning requires comprehensive evaluation of medication history and interaction risks. While pharmacotherapy is crucial for insomnia-associated depression and may achieve notable short-term benefits, key challenges persist regarding long-term efficacy, safety, adherence, and individual variability (111). Addressing these limitations can optimize treatment strategies and guide personalized interventions and future research.
6.1.Pharmacological interventions
Cognitive Behavioral Therapy (CBT) is widely recommended by multiple guidelines as a first-line psychological intervention. However, significant challenges remain in its clinical implementation and dissemination (112). Primarily, limited healthcare resources and a shortage of trained psychotherapists restrict the number of patients who can receive comprehensive CBT (113). Additionally, the time commitment and financial costs associated with multiple therapy sessions further hinder widespread adoption. In current clinical practice, CBT protocols largely rely on standardized templates, which inadequately accommodate the individual characteristics and dynamic psychological states of patients with comorbid depression (114). Moreover, there is a lack of clear consensus and evidence-based guidance tailored to this population.
Moreover, the limited number of therapists with specialized CBT training, coupled with their uneven geographic distribution, further exacerbates disparities in service accessibility. The effectiveness of psychotherapy heavily depends on patients’ subjective initiative and sustained engagement, which are commonly impaired in individuals with depression (115). Symptoms such as diminished motivation, attentional deficits, avoidance behaviors, and negatively biased cognition can all undermine treatment adherence and participation, ultimately affecting therapeutic outcomes. Therefore, despite CBT’s promising theoretical and empirical foundation, its high resource demands, technical complexity, and challenges related to individual compliance hinder standardized and large-scale implementation (116). Further optimization of intervention protocols and dissemination strategies is essential to enhance its practical feasibility and equitable clinical accessibility.
6.2.Gut microbiota-targeted interventions: therapeutic potential and clinical considerations
In recent years, the application of gut microbiota modulators such as probiotics, prebiotics, and synbiotics in comorbid conditions has garnered significant attention. Probiotics, as live microorganisms, have certain strains demonstrated to possess antidepressant and sleep-promoting properties. Bifidobacterium breve CCFM1025 significantly alleviates depressive behaviors by upregulating BDNF and suppressing pro-inflammatory cytokines IL-6 and TNF-α (117). Lactobacillus plantarum JYLP-326 regulates neurotransmitter balance by activating tryptophan hydroxylase 2 (TPH2) (10), thereby enhancing hippocampal 5-HT synthesis. Lactobacillus brevis M2, used in insomnia interventions (118), produces fermentation metabolites that convert into gamma-aminobutyric acid (GABA); dose-dependent activation of GABA receptors subsequently prolongs slow-wave sleep and reduces sleep latency. Lactobacillus fermentum PS150 improves sleep architecture by inhibiting hyperactivation of the HPA axis (119), thereby lowering corticosterone levels. Clinical evidence indicates that multi-strain formulations containing both Bifidobacterium and Lactobacillus strains reduce Hamilton Depression Rating Scale (HAM-D) scores, with more stable effects compared to single-strain interventions (120).
Mechanistic studies have revealed that Bifidobacterium breve CCFM1025 can enhance the production of SCFAs, increase levels of the 5-HT precursor 5-HTP, and elevate hippocampal synaptic 5-HT concentration (121). Probiotics are generally regarded as safe; however, excessive intake or improper use may cause side effects such as bloating, diarrhea, or abdominal discomfort (122). These adverse effects are typically transient and subside as the body adapts to probiotic supplementation. Nonetheless, in certain high-risk populations-such as immunocompromised individuals, patients with severe illnesses, or recent organ transplant recipients-the use of probiotics may increase the risk of infections (123). Despite promising mechanistic and preclinical findings, the clinical translation of microbiota-targeted interventions remains challenging due to strain-specific effects, heterogeneity in microbial signatures, limited clinical validation, and complex host- microbiota interactions. Recent reviews have highlighted the current evidence status of microbiota-based strategies for psychiatric disorders and emphasized the need for rigorous clinical studies and personalized intervention approaches to improve their therapeutic applicability (124). Future studies should optimize individualized microbial and nutritional interventions to improve therapeutic outcomes in insomnia-associated depression.
6.3.Prebiotics and postbiotics: emerging microbiota-based strategies for insomnia-associated depression
Prebiotics, as selective substrates for gut microbiota, include representative compounds such as galacto-oligosaccharides (GOS) and fructo-oligosaccharides (FOS) (125). Studies have shown that prebiotic supplementation containing GOS can modulate gut microbiota composition. However, current clinical evidence remains insufficient to demonstrate consistent improvements in stress-related biomarkers, cortisol awakening response (CAR), or mental health outcomes (126). Therefore, the potential effects of GOS on emotional regulation and stress responses require further validation in well-designed clinical studies.
Lactobacillus rhamnosus plus FOS alleviates coronary artery disease with comorbid depression, significantly lowering BDI scores, LPS, and hs-CRP levels, outperforming monotherapy (127). Postbiotics, defined as non-viable microbial products, also exhibit significant bioactivity. For example, cell lysates of Lactobacillus paracasei have been confirmed to cross the intestinal barrier and, via the vagus nerve, upregulate N-acetylserotonin, thereby shortening sleep latency and enhancing sleep efficiency (128). Their heat stability supports functional food potential. Further details on gut modulators are summarized in Table 3. Gut microbiota modulators act by reshaping microbial diversity, enhancing gut-brain barrier integrity, balancing neurotransmitters, and reducing inflammation. Future studies should optimize personalized strain combinations to improve clinical outcomes in comorbid insomnia and depression.
Table 3Microbiota that regulates sleep and improves depression.
Category Representative bacteria Function Pathways Key targets Model Evidence References
Probiotic Lactobacillus rhamnosus ↑ GABA expression GABA GABA receptor Mouse model PE (129)
Probiotic Bifidobacterium longum ↑ 5-HT synthesis, ↓ depressant Tryptophan,5-HT TPH/serotonergic pathways Adults with IBS RCE (130)
Probiotic Lactobacillus plantarum ↑ Sleep, ↓ inflammatory HPA axis CRH, ACTH, GR CUMS rats PE (131)
Opportunistic pathogen Desulfovibrio spp Damages intestinal barrier, ↑ inflammatory Gut barrier ZO-1, Occludin Patients with postpartum depression OHE (132)
Opportunistic pathogen Prevotella spp ↑ indole metabolites, ↑ AhR AhR AhR Mechanistic review PM (133)
Probiotic Faecalibacterium prausnitzii ↓ inflammatory, ↑ SCFA SCFA GPR43 Patients with ulcerative colitis OHE (134)
Opportunistic pathogen Clostridium spp ↓ 5-HT, ↑ mood regulation Tryptophan metabolism TPH, SERT Antibiotic induced dysbiosis in mice PE (125)
Probiotic Akkermansia muciniphila ↑ intestinal health, ↓ inflammation Mucosal barrier regulation MUC2, TFF3 Colitis mice PE (135)
Opportunistic pathogen Escherichia coli ↑ Triggers immune, ↑ LPS TLR4/NF-κB TLR4, NF-κB E. coli infection in mice PE (136)
Probiotic Roseburia spp ↑ butyrate, ↓ inflammation SCFA-GPR41/43 GPR41, GPR43 Mechanistic review PM (137)
Probiotic Parabacteroides distasonis ↓ bile acids, ↓ inflammation HCA17/ketoDCA TrkB/BDNF CUS mice PE (138)
Probiotic Streptococcus thermophilus ↑Neurotransmitter metabolism Dopamine, 5-HT modulation TPH, SERT, DAT PCPA induced insomnia mice PE (128)
Probiotic Eubacterium rectale ↑ Butyrate, ↓ inflammation NF-κB MyD88, TLR4 Human gastrointestinal lymphoma samples and mouse model PE/OHE (139)
PE, preclinical evidence; OHE, observational human evidence; RCE, randomized clinical evidence; H/PM, hypothesis or proposed mechanism. ↑, indicates promote/increase; ↓, indicates inhibition/decrease.
6.4.Immune-targeted therapies: modulating neuroinflammation and immune dysregulation in insomnia-associated depression
Immune dysregulation drives insomnia-associated depression, marked by elevated pro-inflammatory cytokines and reduced anti-inflammatory (140). This disrupts tryptophan metabolism, impairing 5-HT synthesis and dysregulating NE/DA pathways, which reduces neuroplasticity, dysregulates the HPA axis, and disturbs sleep. These effects create a vicious cycle linking poor sleep and depression (141). IL-2 and IL-15 improve IAD by activating T cells, enhancing anti-inflammatory responses, and restoring neurotransmitter balance. Aspirin and ibuprofen inhibit COX, decreasing IL-1β, IL-6 and TNF-α, alleviating neuroinflammation, and boosting 5-HT and SSRI efficacy (142). Glucocorticoids stabilize the HPA axis, lowering cortisol, reducing inflammation, protecting neurons, and improving mood and sleep (69). Clinical trials demonstrate that anti-inflammatory biologics (tocilizumab, etanercept, infliximab) lower depression scores by blocking inflammatory signaling and restoring neurotransmitter balance (143, 144). Immune pathways thus represent crucial IAD treatment targets. Combining precise anti-inflammatory modulation with personalized non-drug therapies may optimize IAD management. Detailed information on drugs that improve depression by acting on the immune axis is shown in Table 4.
Table 4Drugs and compounds targeting the immune axis in depression.
Intervention Therapeutic effects Major pathway/targets Model and regime Ref.
Fluoxetine Reduced depressive-like behavior and A1 astrocyte activation 5-HT2BR/β-arrestin2 CMS mice; 10 mg/kg/day, i.p., 4 weeks (145)
Minocycline Reduced depressive-like behavior and neuroinflammation Microglial polarization; BDNF/TrkB CUMS rats; 40 mg/kg/day, 45 days (146)
Astragaloside IV Reduced depressive-like behavior and hippocampal inflammation PPARγ/NF-κB/NLRP3 Restraint-stress mice; 16–64 mg/kg/day, i.g (147)
Baicalin Reduced depressive-like behavior and neuroinflammation PI3K/AKT/FoxO1; TLR4 CUMS mice; 30–60 mg/kg/day, oral, 5 weeks (148)
Gypenosides Reduced depressive-like behavior and microglial activation IKKα/IKKβ/NF-κB CUMS mice; 100 mg/kg/day, oral, 4 weeks (149)
Safflower extract Reduced depressive-like behavior and inflammatory cytokines TLR4/p38/NF-κB/NLRP3 CUMS mice; 10–30 mg/kg/day, oral, 4 weeks (150)
Brilliant Blue G Reduced LPS-induced depressive-like behavior and TNF-α P2X7R LPS mice; 50 mg/kg, i.p., before LPS (151)
Melatonin Reduced LPS-induced depressive-like behavior and neuroinflammation TNF-α; BDNF; oxidative stress LPS mice; 10 mg/kg, i.p., before LPS (152)
CMS, chronic mild stress; MDD, major depressive disorder; i.p., intraperitoneal; i.g., intragastric; 5-HT2BR, serotonin 2B receptor; P2X7R, P2X7 receptor; PPARγ, peroxisome proliferator-activated receptor γ. Brilliant Blue G (BBG) is included as an experimental P2X7R antagonist and mechanistic tool compound rather than an established clinical therapeutic.
7.Traditional Chinese medicine formulations for treating insomnia-associated depression
Traditional Chinese Medicine (TCM) employs multi-herb formulas based on the “Jun-Chen-Zuo-Shi” principle to maximize efficacy and minimize toxicity (153). These formulas act through multiple components and pathways, matching disease complexity. For instance, Xiaoyao San (containing Chaihu, Baishao, Danggui, etc.) has shown potential benefits for insomnia-associated depression in the context of liver qi stagnation (154). Pharmacological studies suggest that Xiaoyao San may alleviate depression through modulation of the HPA axis and microbiota-gut-brain axis, potentially involving neuroendocrine and neuroimmune pathways. Enhanced formulations like Jieyu Pill (with Curcuma, Albizia bark, and Gancao-Maidazao) may further regulate liver qi and heart-mind harmony, with reported benefits for sleep disturbances, anxiety, palpitations, and autonomic dysfunction (155). For heart-spleen deficiency, Guipi Decoction is traditionally used to replenish Qi, fortify the spleen, nourish blood, and calm the mind, with reported effects on mood, fatigue, insomnia, and memory (156). The reported effects and proposed mechanisms of Chinese herbal formulas for insomnia-associated depression are summarized in Table 5.
Table 5Improving insomnia-related depression with Chinese herbal medicine compounds.
Name Effects Nature/flavor Meridians Pathways Targets References
Xiaoyao San Soothe liver, regulate Qi, relieve depressive insomnia Sweet, slightly bitter Liver, Spleen PI3K-Akt, HPA axis, microbiota-gut-brain axis AKT1, TP53, VEGFA, 5‑HT (157)
Jiawei Xiaoyao San Enhanced antidepressant effect, improve sleep Slightly sweet, bitter Liver, Spleen HPA axis, neurotrophic BDNF, CORT, 5‑HT (158)
Jieyu Wan Soothe liver and heart, relieve anxiety and palpitations Pungent, sweet Liver, Heart Monoamine neurotransmitter 5‑HT, DA (159)
Guipi Tang & Guipi Wan Tonify Qi and blood, calm mind, treat depressive insomnia Sweet, warm Heart, Spleen Immunomodulation, neurotransmitter balance BDNF, neurotrophic factors (160)
Suanzaoren Tang Tranquilize mind, improve sleep with irritability Sweet, sour, slightly warm Heart, Liver GABAergic, serotonergic GABA, 5‑HT (161)
Kaixin San Nourish heart and spleen, relieve depressive insomnia Sweet, mild Heart, Spleen Synaptic, monoamine GABA, monoamines, neurotrophic proteins (162)
Chaihu Longgu Muli Tang Regulate liver Qi, sedate heart and mind Bitter, sweet, neutral Liver, Heart HPA axis CORT, HPA axis proteins (163)
Guizhi Gancao Longgu Muli Tang Calm spirit, relieve palpitations and insomnia Sweet, pungent, neutral Heart, Lung, Heart Central nervous system Autonomic regulators (164)
Xiaochaihu Tang Harmonize Shaoyang, relieve emotional imbalance Bitter, slightly cold Liver, Gallbladder Monoaminergic neurotransmission NE, 5‑HT (165)
Baihe Dihuang Tang Anti-depressive, anxiolytic, neuroprotective Sweet, cool Heart, Lung, Kidney Inflammatory regulation, epigenetic neuroprotection CORT, ILs, HPA factors, miRNA-mRNA networks (166)
Sinisan Soothe liver, harmonize spleen, improve sleep Bitter, sweet, neutral Liver, Spleen Apoptosis, neurotransmitter modulation CREB1, NOS3, CASP3, SLC6A4 (94)
Analysis of China’s patent data reveals the top 10 anti-depression herbs: turmeric, bupleurum, white peony, sour jujube seed, poria, angelica, polygala, atractylodes, acorus, and salvia. These herbs are traditionally used for patterns involving qi stagnation, blood stasis, and deficiency, primarily affecting the liver, heart, spleen, and lungs (157). Their traditional functions include liver-soothing, spleen-heart fortification, and qi and blood regulation, offering insights for further research on depression treatment and drug development.
8.Discussion
Insomnia is closely associated with the onset, persistence, and recurrence of depression, yet the biological basis of this comorbidity cannot be fully explained by circadian disruption alone. The evidence reviewed here supports a broader model in which sleep loss alters microbial composition and function, weakens intestinal barrier integrity, and changes the production of immunoregulatory metabolites. Current evidence suggests that sleep disruption is associated with alterations in microbial composition and function, although a consistent microbial signature of insomnia associated depression has not yet been established. Altered microbial metabolism may affect tryptophan availability, kynurenine pathway activity, serotonin related signaling, and the production of immunoregulatory metabolites, thereby influencing neuroimmune and synaptic processes relevant to mood regulation. The main value of the microbiota immune synapse framework lies in connecting peripheral disturbances induced by insomnia with central changes relevant to depression, rather than treating microbial dysbiosis, inflammation, and synaptic dysfunction as independent abnormalities.
Repeated sleep disruption may produce sustained or dysregulated HPA axis activity, although cortisol responses vary according to insomnia phenotype, sampling time, disease duration, and comorbid conditions. HPA axis dysregulation, microbial metabolite depletion, and epithelial stress may jointly weaken tight junction integrity and increase exposure to microbial products such as lipopolysaccharide. These signals can activate innate immune pathways, including TLR4 and NF κB signaling, and promote the release of IL 1β, IL 6, and TNF α. These mediators may affect the brain through humoral, neural, and cellular routes, alter blood brain barrier function, activate microglia and astrocytes, and interfere with neurotrophic signaling and synaptic remodeling. This interpretation places immune dysregulation at the interface between microbial disturbance and synaptic injury and provides a mechanistic basis for evaluating nutritional interventions.
The HPA axis and vagal pathways may reinforce this network by coupling sleep and stress signals with intestinal, microbial, and immune responses. This network is likely to operate bidirectionally, because inflammation and altered microbial metabolism may also disturb sleep architecture and stress regulation, thereby maintaining depressive symptoms. Microbiota transfer experiments from sleep deprived donors provide evidence that microbial alterations can contribute to behavioral and neuroimmune abnormalities in recipient animals. Accordingly, the microbiota immune synapse model proposed in this review should be interpreted as an integrative framework rather than a fully validated causal pathway in humans. These findings support causality at the preclinical level but do not establish that gut dysbiosis alone causes clinically diagnosed insomnia associated depression in humans. Current treatments, including cognitive behavioral therapy for insomnia, pharmacological agents, light-based interventions, and selected nutritional approaches, can improve sleep or mood outcomes. Evidence that these treatments fail because they target isolated pathways is limited, and several may already influence immune or microbial processes indirectly. The more relevant limitation is that few clinical trials have simultaneously assessed microbial function, immune activity, synaptic indicators, sleep outcomes, and depressive symptoms. Mechanistic validation is particularly limited in human comorbidity cohorts, and reliable biomarkers for selecting patients or predicting treatment response have not been established.
The principal contribution of this review is the integration of three levels of pathology that are often examined separately: insomnia associated microbial dysfunction, peripheral and central immune dysregulation, and synaptic impairment. Within this framework, immune signaling is not treated as one pathway among many but as the mechanistic interface that translates intestinal disturbance into altered neural plasticity. This framework supports the evaluation of microbiota targeted nutritional interventions as adjunctive, mechanism informed strategies. Their potential advantage lies in acting on several modifiable components of the proposed loop, including microbial metabolism, epithelial barrier integrity, inflammatory signaling, and synaptic support. Their clinical value will depend on identifying responsive patient subgroups and demonstrating that changes in these mechanisms mediate symptom improvement.
Compared with existing literature, this review brings molecular signaling, immune inflammation, and synaptic dysfunction into a microbiota immune synapse framework. Within this framework, immune dysregulation may serve as an important link between insomnia related gut microbial changes, impaired synaptic plasticity, and depressive symptoms. These processes may further interact to form a pathological cycle involving sleep disturbance, microbial imbalance, inflammation, and synaptic injury. This integrated view may provide a clearer basis for developing nutritional strategies that act on several related pathways rather than a single target.
Future studies may benefit from combining metagenomics, metabolomics, immune profiling, and sleep assessment to clarify the temporal sequence of microbiota immune neural changes. Longitudinal designs could help distinguish early contributors from secondary alterations. Repeated measurements of microbial metabolites, intestinal barrier markers, inflammatory mediators, and sleep parameters may also improve the evaluation of nutritional interventions. Attention to sampling time is important because microbial metabolism, cortisol secretion, and inflammatory responses can vary across circadian cycles. Clinical translation will likely depend on standardized protocols and well-designed trials that assess sleep, depressive symptoms, microbial function, and immune outcomes in an integrated manner.
9.Conclusion
The microbiota immune synapse axis provides an integrative framework for understanding insomnia related depression and may guide the development of food derived bioactive compounds and precision nutritional strategies targeting microbial dysbiosis, immune imbalance, and synaptic dysfunction.
Funding Statement
The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the Major Science and Technology Special Project of the Science and Technology Department of Sichuan Province (2024ZDZX0019) and the Special Program for Doctoral Students under the Young Elite Scientists Sponsorship Program of the China Association for Science and Technology (156O36000003245).
Footnotes
Edited by: Cassiano Felippe Gonçalves-de-Albuquerque, Rio de Janeiro State Federal University, Brazil
Reviewed by: Adriano Dos Santos, University of Bern, Switzerland
Hanane El Fatimi, Mohammed VI University of Health Sciences, Morocco
Author contributions
DT: Writing – original draft, Data curation, Resources, Writing – review & editing. HQ: Writing – review & editing, Software, Data curation. ZL: Writing – review & editing. JX: Validation, Writing – original draft, Supervision. JW: Writing – review & editing, Funding acquisition, Formal analysis.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
Sutton EL.
Insomnia. Ann Intern Med. (2021) 174:ITC33–48. doi: 10.7326/AITC202103160
2.
Perlis ML, Posner D, Riemann D, Bastien CH, Teel J, Thase M.
Insomnia. Lancet. (2022) 400:1047–60. doi: 10.1016/S0140-6736(22)00879-0
3.
Christiaens A, Aubert CE, Wichniak A, Casanovas AS, Spinewine A.
Deprescribing benzodiazepine receptor agonists for insomnia in older adults. Lancet. (2023) 402:1421–2. doi: 10.1016/S0140-6736(23)01562-3
4.
Yin X, Li W, Liang T, Lu B, Yue H, Li S, et al.
Effect of electroacupuncture on insomnia in patients with depression: A randomized clinical trial. JAMA Netw Open. (2022) 5:e2220563. doi: 10.1001/jamanetworkopen.2022.20563
5.
Blom K, Forsell E, Hellberg M, Svanborg C, Jernelöv S, Kaldo V.
Psychological treatment of comorbid insomnia and depression: A double-blind randomized placebo-controlled trial. Psychother Psychosom. (2024) 93:100–13. doi: 10.1159/000536063
6.
Li L, Wu C, Gan Y, Qu X, Lu Z.
Insomnia and the risk of depression: A meta-analysis of prospective cohort studies. BMC Psychiatry. (2016) 16:375. doi: 10.1186/s12888-016-1075-3
7.
Cunnington D, Junge MF, Fernando AT.
Insomnia: Prevalence, consequences and effective treatment. Med J Aust. (2013) 199:S36–40. doi: 10.5694/MJA13.10718
8.
Mirchandaney R, Barete R, Asarnow LD.
Moderators of cognitive behavioral treatment for insomnia on depression and anxiety outcomes. Curr Psychiatry Rep. (2022) 24:121–8. doi: 10.1007/s11920-022-01326-3
9.
Pandi-Perumal SR, Monti JM, Burman D, Karthikeyan R, BaHammam AS, Spence DW, et al.
Clarifying the role of sleep in depression: A narrative review. Psychiatry Res. (2020) 291:113239. doi: 10.1016/j.psychres.2020.113239
10.
Zhu R, Fang Y, Li H, Liu Y, Wei J, Zhang S, et al.
Psychobiotic Lactobacillus plantarum JYLP-326 relieves anxiety, depression, and insomnia symptoms in test-anxious college students via modulating the gut microbiota and its metabolism. Front Immunol. (2023) 14:1158137. doi: 10.3389/fimmu.2023.1158137
11.
Bi C, Guo S, Hu S, Chen J, Ye M, Liu Z.
The microbiota-gut-brain axis and its modulation in the therapy of depression: Comparison of efficacy of conventional drugs and traditional Chinese medicine approaches. Pharmacol Res. (2022) 183:106372. doi: 10.1016/j.phrs.2022.106372
12.
Li Y, Hao Y, Fan F, Zhang B.
The role of microbiome in insomnia, circadian disturbance and depression. Front Psychiatry. (2018) 9:669. doi: 10.3389/fpsyt.2018.00669
13.
Zhu Z, Cheng Y, Liu X, Xu X, Ding W, Ling Z, et al.
The microbiota-gut-brain axis in depression: Unraveling the relationships and therapeutic opportunities. Front Immunol. (2025) 16:1644160. doi: 10.3389/fimmu.2025.1644160
14.
Feng W, Yang Z, Liu Y, Chen R, Song Z, Pan G, et al.
Gut microbiota: A new target of traditional Chinese medicine for insomnia. BioMed Pharmacother. (2023) 160:114344. doi: 10.1016/j.biopha.2023.114344
15.
Lu Y, Yu X, Wang Z, Kong L, Jiang Z, Shang R, et al.
Microbiota-gut-brain axis: Natural antidepressants molecular mechanism. Phytomedicine. (2024) 134:156012. doi: 10.1016/j.phymed.2024.156012
16.
Lee DY, Baek JS, Shin YJ, Kim DH.
Alleviation of immobilization stress or fecal microbiota-induced insomnia and depression-like behaviors in mice by Lactobacillus plantarum and its supplement. Nutrients. (2024) 16:3711. doi: 10.3390/nu16213711
17.
Lee HJ, Hong JK, Kim JK, Kim DH, Jang SW, Han SW, et al.
Effects of probiotic NVP-1704 on mental health and sleep in healthy adults: An 8-week randomized, double-blind, placebo-controlled trial. Nutrients. (2021) 13:2660. doi: 10.3390/nu13082660
18.
Li J, Li Y, Zhao J, Li L, Wang Y, Chen F, et al.
Effects of Bifidobacterium breve 207-1 on regulating lifestyle behaviors and mental wellness in healthy adults based on the microbiome-gut-brain axis: A randomized, double-blind, placebo-controlled trial. Eur J Nutr. (2024) 63:2567–85. doi: 10.1007/s00394-024-03447-2
19.
Faraji N, Payami B, Ebadpour N, Gorji A.
Vagus nerve stimulation and gut microbiota interactions: A novel therapeutic avenue for neuropsychiatric disorders. Neurosci Biobehav Rev. (2025) 169:105990. doi: 10.1016/j.neubiorev.2024.105990
20.
Lee SH, Han C, Shin C.
IUPHAR review: Microbiota-gut-brain axis and its role in neuropsychiatric disorders. Pharmacol Res. (2025) 216:107749. doi: 10.1016/j.phrs.2025.107749
21.
Matenchuk BA, Mandhane PJ, Kozyrskyj AL.
Sleep, circadian rhythm, and gut microbiota. Sleep Med Rev. (2020) 53:101340. doi: 10.1016/j.smrv.2020.101340
22.
Zhao Y, Kang Y, Zhao Z, Yang G, Gao Y, Gao L, et al.
Lacticaseibacillus rhamnosus TF318 prevents depressive behavior in rats by inhibiting HPA-axis hyperactivity and upregulating BDNF expression. Neurosci Lett. (2023) 814:137460. doi: 10.1016/j.neulet.2023.137460
23.
Li T, Fang J, Tang S, Du H, Zhao L, Wang Y, et al.
PM2.5 exposure associated with microbiota gut-brain axis: Multi-omics mechanistic implications from the BAPE study. Innovation (Camb). (2022) 3:100213. doi: 10.1016/j.xinn.2022.100213
24.
Liu P, Liu Z, Wang J, Wang J, Gao M, Zhang Y, et al.
Immunoregulatory role of the gut microbiota in inflammatory depression. Nat Commun. (2024) 15:3003. doi: 10.1038/s41467-024-47273-w
25.
Xiong RG, Li J, Cheng J, Zhou DD, Wu SX, Huang SY, et al.
The role of gut microbiota in anxiety, depression, and other mental disorders as well as the protective effects of dietary components. Nutrients. (2023) 15:3258. doi: 10.3390/nu15143258
26.
Zang Y, Lai X, Li C, Ding D, Wang Y, Zhu Y.
The role of gut microbiota in various neurological and psychiatric disorders: An evidence mapping based on quantified evidence. Mediators Inflammation. (2023) 2023:5127157. doi: 10.1155/2023/5127157
27.
Gao M, Wang J, Liu P, Tu H, Zhang R, Zhang Y, et al.
Gut microbiota composition in depressive disorder: A systematic review, meta-analysis, and meta-regression. Transl Psychiatry. (2023) 13:379. doi: 10.1038/s41398-023-02670-5
28.
Xie S, Wang C, Song J, Zhang Y, Wang H, Chen X, et al.
Lacticaseibacillus rhamnosus KY16 improves depression by promoting intestinal secretion of 5-HTP and altering the gut microbiota. J Agric Food Chem. (2024) 72:21560–73. doi: 10.1021/acs.jafc.4c03870
29.
Zhang X, Hu H, Zhang Y, Hu S, Lu J, Peng W, et al.
Dietary capsaicin exacerbates gut microbiota dysbiosis and mental disorders in type 1 diabetes mice. Nutrients. (2025) 17:593. doi: 10.3390/nu17030593
30.
Mao Q, Zhang H, Zhang Z, Lu Y, Pan J, Guo D, et al.
Co-decoction of Lilii bulbus and Radix Rehmannia Recens and its key bioactive ingredient verbascoside inhibit neuroinflammation and intestinal permeability associated with chronic stress-induced depression via the gut microbiota-brain axis. Phytomedicine. (2024) 129:155510. doi: 10.1016/j.phymed.2024.155510
31.
Serna-Rodríguez MF, Bernal-Vega S, de la Barquera JAO, Camacho-Morales A, Pérez-Maya AA.
The role of damage associated molecular pattern molecules (DAMPs) and permeability of the blood-brain barrier in depression and neuroinflammation. J Neuroimmunol. (2022) 371:577951. doi: 10.1016/j.jneuroim.2022.577951
32.
Kouba BR, de Araujo Borba L, Borges de Souza P, Gil-Mohapel J, Rodrigues ALS.
Role of inflammatory mechanisms in major depressive disorder: From etiology to potential pharmacological targets. Cells. (2024) 13:423. doi: 10.3390/cells13050423
33.
Zhou J, Wu X, Li Z, Zou Z, Dou S, Li G, et al.
Alterations in gut microbiota are correlated with serum metabolites in patients with insomnia disorder. Front Cell Infect Microbiol. (2022) 12:722662. doi: 10.3389/fcimb.2022.722662
34.
Li Y, Zhang B, Zhou Y, Wang D, Liu X, Li L, et al.
Gut microbiota changes and their relationship with inflammation in patients with acute and chronic insomnia. Nat Sci Sleep. (2020) 12:895–905. doi: 10.2147/NSS.S271927
35.
Li L, Meng Z, Huang Y, Xu L, Chen Q, Qiao D, et al.
Chronic sleep deprivation causes anxiety, depression and impaired gut barrier in female mice- Correlation analysis from fecal microbiome and metabolome. Biomedicines. (2024) 12:2654. doi: 10.3390/biomedicines12122654
36.
Zhang Q, Yun Y, An H, Zhao W, Ma T, Wang Z, et al.
Gut microbiome composition associated with major depressive disorder and sleep quality. Front Psychiatry. (2021) 12:645045. doi: 10.3389/fpsyt.2021.645045
37.
Tanaka A, Sanada K, Miyaho K, Tachibana T, Kurokawa S, Ishii C, et al.
The relationship between sleep, gut microbiota, and metabolome in patients with depression and anxiety: A secondary analysis of the observational study. PloS One. (2023) 18:e0296047. doi: 10.1371/journal.pone.0296047
38.
Seong HJ, Baek Y, Lee S, Jin HJ.
Gut microbiome and metabolic pathways linked to sleep quality. Front Microbiol. (2024) 15:1418773. doi: 10.3389/fmicb.2024.1418773
39.
Li Z, Shu Y, Liu D, Xie S, Xian L, Luo J, et al.
Pink1/Parkin signaling mediates pineal mitochondrial autophagy dysfunction and its biological role in a comorbid rat model of depression and insomnia. Brain Res Bull. (2025) 220:111141. doi: 10.1016/j.brainresbull.2024.111141
40.
Sarawi WS.
Neurochemical insights into the role of tryptophan metabolites and kynurenine pathway in insomnia and its psychological and neurological comorbidities. Mol Neurobiol. (2025) 62:15450–77. doi: 10.1007/s12035-025-05210-y
41.
Tiwari S, Paramanik V.
Role of probiotics in depression: Connecting dots of gut-brain-axis through hypothalamic-pituitary adrenal axis and tryptophan/kynurenic pathway involving indoleamine-2,3-dioxygenase. Mol Neurobiol. (2025) 62:7230–41. doi: 10.1007/s12035-025-04708-9
42.
Deng Y, Zhou M, Wang J, Yao J, Yu J, Liu W, et al.
Involvement of the microbiota-gut-brain axis in chronic restraint stress: Disturbances of the kynurenine metabolic pathway in both the gut and brain. Gut Microbes. (2021) 13:1–16. doi: 10.1080/19490976.2020.1869501
43.
Zhao R, Zhou Y, Shi H, Ye W, Lyu Y, Wen Z, et al.
Effect of gestational diabetes on postpartum depression-like behavior in rats and its mechanism. Nutrients. (2022) 14:1229. doi: 10.3390/nu14061229
44.
Zheng L, Xin J, Ye H, Sun N, Gan B, Gong X, et al.
Lactobacillus johnsonii YH1136 alleviates schizophrenia-like behavior in mice: A gut-microbiota-brain axis hypothesis study. BMC Microbiol. (2025) 25:191. doi: 10.1186/s12866-025-03893-w
45.
Wan Z, Zhang X, Jia X, Qin Y, Sun N, Xin J, et al.
Lactobacillus johnsonii YH1136 plays a protective role against endogenous pathogenic bacteria induced intestinal dysfunction by reconstructing gut microbiota in mice exposed at high altitude. Front Immunol. (2022) 13:1007737. doi: 10.3389/fimmu.2022.1007737
46.
Jiang C, Chen Y, Sun T.
From the gut to the brain, mechanisms and clinical applications of γ-aminobutyric acid (GABA) on the treatment of anxiety and insomnia. Front Neurosci. (2025) 19:1570173. doi: 10.3389/fnins.2025.1570173
47.
Tufail T, Ain HBU, Virk MS, Ashraf J, Ahmed Z, Khalil AA, et al.
GABA (γ-aminobutyric acid) enrichment and detection methods in cereals: Unlocking sustainable health benefits. Food Chem. (2025) 464:141750. doi: 10.1016/j.foodchem.2024.141750
48.
Khan MT, Zohair M, Khan A, Kashif A, Mumtaz S, Muskan F.
From gut to brain: The roles of intestinal microbiota, immune system, and hormones in intestinal physiology and gut-brain-axis. Mol Cell Endocrinol. (2025) 607:112599. doi: 10.1016/j.mce.2025.112599
49.
Pan J, Lu Y, Wang S, Ma T, Xue X, Zhang Z, et al.
Synergistic neuroprotective effects of two natural medicinal plants against CORT-induced nerve cell injury by correcting neurotransmitter deficits and inflammation imbalance. Phytomedicine. (2023) 121:155102. doi: 10.1016/j.phymed.2023.155102
50.
Medina-Rodríguez EM, Martínez-Raga J, Sanz Y.
Intestinal barrier, immunity and microbiome: Partners in the depression crime. Pharmacol Rev. (2024) 76:956–69. doi: 10.1124/pharmrev.124.001202
51.
Fang M, Li Y, Liao Z, Wang G, Cao Q, Li Y, et al.
Lipopolysaccharide-binding protein expression is increased by stress and inhibits monoamine synthesis to promote depressive symptoms. Immunity. (2023) 56:620–634.e11. doi: 10.1016/j.immuni.2023.02.002
52.
Tang N, Zeng Y, He G, Chen S.
Interference between immune cells and insomnia: A bibliometric analysis from 2000 to 2023. Front Neurol. (2025) 16:1486548. doi: 10.3389/fneur.2025.1486548
53.
De Crescenzo F, D'Alò GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N, et al.
Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: A systematic review and network meta-analysis. Lancet. (2022) 400:170–84. doi: 10.1016/S0140-6736(22)00878-9
54.
Ariño H, Muñoz-Lopetegi A, Martinez-Hernandez E, Armangue T, Rosa-Justicia M, Escudero D, et al.
Sleep disorders in anti-NMDAR encephalitis. Neurology. (2020) 95:e671–84. doi: 10.1212/WNL.0000000000009987
55.
Schipper SBJ, Van Veen MM, Elders PJM, van Straten A, Van Der Werf YD, Knutson KL, et al.
Sleep disorders in people with type 2 diabetes and associated health outcomes: A review of the literature. Diabetologia. (2021) 64:2367–77. doi: 10.1007/s00125-021-05541-0
56.
Du Y, He B, Wu B, Yan T, Jia Y.
Suanzaoren decoction improves depressive-like behaviors by regulating the microbiota-gut-brain axis via inhibiting TLR4/NFκB/NLRP3 inflammation signal pathway. J Chem Neuroanat. (2023) 134:102349. doi: 10.1016/j.jchemneu.2023.102349
57.
Zhong Z, Liu J, Luo Y, Wu M, Qiu F, Zhao H, et al.
Jujuboside A regulates calcium homeostasis and structural plasticity to alleviate depression-like behavior via Shh signaling in immature neurons. Drug Des Devel Ther. (2024) 18:4565–84. doi: 10.2147/DDDT.S479055
58.
Li ZR, Liu DG, Xie S, Wang YH, Han YS, Li CY, et al.
Sleep deprivation leads to further impairment of hippocampal synaptic plasticity by suppressing melatonin secretion in the pineal gland of chronically unpredictable stress rats. Eur J Pharmacol. (2022) 930:175149. doi: 10.1016/j.ejphar.2022.175149
59.
Sang D, Lin K, Yang Y, Ran G, Li B, Chen C, et al.
Prolonged sleep deprivation induces a cytokine-storm-like syndrome in mammals. Cell. (2023) 186:5500–5516.e21. doi: 10.1016/j.cell.2023.10.025
60.
Ahmad AS, Ottallah H, Maciel CB, Strickland M, Doré S.
Role of the L-PGDS-PGD2-DP1 receptor axis in sleep regulation and neurologic outcomes. Sleep. (2019) 42:zsz073. doi: 10.1093/sleep/zsz073
61.
Qian F, Nettleford SK, Zhou J, Arner BE, Hall MA, Sharma A, et al.
Activation of GPR44 decreases severity of myeloid leukemia via specific targeting of leukemia initiating stem cells. Cell Rep. (2023) 42:112794. doi: 10.1016/j.celrep.2023.112794
62.
Ayyaswamy S, Shi H, Zhang B, Bryan RM, Durgan DJ.
Obstructive sleep apnea-induced hypertension is associated with increased gut and neuroinflammation. J Am Heart Assoc. (2023) 12:e029218. doi: 10.1161/JAHA.122.029218
63.
Xu J, Wu Y, Xu Y, Li Y, He X, Zhang H, et al.
Molecular basis for ligand recognition and receptor activation of the prostaglandin D2 receptor DP1. Proc Natl Acad Sci USA. (2025) 122:e2501902122. doi: 10.1073/pnas.2501902122
64.
Asarnow LD.
Depression and sleep: What has the treatment research revealed and could the HPA axis be a potential mechanism? Curr Opin Psychol. (2020) 34:112–6. doi: 10.1016/j.copsyc.2019.12.002
65.
Ye M, Lee S, Yu HJ, Kim KR, Park HJ, Kang IC, et al.
Sedative-hypnotic effects of Glycine max Merr. extract and its active ingredient genistein on electric-shock-induced sleep disturbances in rats. Int J Mol Sci. (2023) 24:7043. doi: 10.3390/ijms24087043
66.
Gupta AK, Gupta S, Mehan S, Khan Z, Das Gupta G, Narula AS.
Exploring the connection between BDNF/TrkB and AC/cAMP/PKA/CREB signaling pathways: Potential for neuroprotection and therapeutic targets for neurological disorders. Mol Neurobiol. (2025). doi: 10.1007/s12035-025-05001-5
67.
Vaseghi S, Mostafavijabbari A, Alizadeh MS, Ghaffarzadegan R, Kholghi G, Zarrindast MR.
Intricate role of sleep deprivation in modulating depression: Focusing on BDNF, VEGF, serotonin, cortisol, and TNF-α. Metab Brain Dis. (2023) 38:195–219. doi: 10.1007/s11011-022-01124-z
68.
Birch JN, Vanderheyden WM.
The molecular relationship between stress and insomnia. Adv Biol (Weinh). (2022) 6:e2101203. doi: 10.1002/adbi.202101203
69.
Szeszko PR, Lehrner A, Yehuda R.
Glucocorticoids and hippocampal structure and function in PTSD. Harv Rev Psychiatry. (2018) 26:142–57. doi: 10.1097/HRP.0000000000000188
70.
Zhang Y, Luo Y, Hou X, Lu K, He Y, Yang B, et al.
Xiaoyao powder alleviates the hippocampal neuron damage in chronic unpredictable mild stress-induced depression model rats in hippocampus via connexin 43Cx43/glucocorticoid receptor/brain-derived neurotrophic factor signaling pathway. Bioengineered. (2022) 13:383–94. doi: 10.1080/21655979.2021.2005744
71.
Takahashi G, Asanuma F, Suzuki N, Hattori M, Sakamoto S, Kugimiya A, et al.
Effect of the potent and selective DP1 receptor antagonist, asapiprant (S-555739), in animal models of allergic rhinitis and allergic asthma. Eur J Pharmacol. (2015) 765:15–23. doi: 10.1016/j.ejphar.2015.08.003
72.
Kenna HA, Poon AW, de los Angeles CP, Koran LM.
Psychiatric complications of treatment with corticosteroids: Review with case report. Psychiatry Clin Neurosci. (2011) 65:549–60. doi: 10.1111/j.1440-1819.2011.02260.x
73.
Lu Y, Ho CS, Liu X, Chua AN, Wang W, McIntyre RS, et al.
Chronic administration of fluoxetine and pro-inflammatory cytokine change in a rat model of depression. PloS One. (2017) 12:e0186700. doi: 10.1371/journal.pone.0186700
74.
Brown ES, Bobadilla L, Rush AJ.
Ketoconazole in bipolar patients with depressive symptoms: A case series and literature review. Bipolar Disord. (2001) 3:23–9. doi: 10.1034/j.1399-5618.2001.030103.x
75.
Hsiao CC.
Difference in pre- and post-treatment plasma DHEA levels were significantly and positively correlated with difference in pre- and post-treatment Hamilton depression scores following successful therapy for major depression. Psychoneuroendocrinology. (2006) 31:839–46. doi: 10.1016/j.psyneuen.2006.03.008
76.
Nakatsugi S, Sugimoto N, Furukawa M.
Effects of non-steroidal anti-inflammatory drugs on prostaglandin E2 production by cyclooxygenase-2 from endogenous and exogenous arachidonic acid in rat peritoneal macrophages stimulated with lipopolysaccharide. Prostaglandins Leukot Essent Fatty Acids. (1996) 55:451–7. doi: 10.1016/S0952-3278(96)90130-1
77.
Greiff L, Persson CG, Svensson C, Enander I, Andersson M.
Loratadine reduces allergen-induced mucosal output of alpha 2-macroglobulin and tryptase in allergic rhinitis. J Allergy Clin Immunol. (1995) 96:97–103. doi: 10.1016/S0091-6749(95)70038-2
78.
Fahr A.
Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet. (1993) 24:472–95. doi: 10.2165/00003088-199324060-00004
79.
Ertenli I, Ozer S, Kiraz S, Apras SB, Akdogan A, Karadag O, et al.
Infliximab, a TNF-α antagonist treatment in patients with ankylosing spondylitis: The impact on depression, anxiety and quality of life level. Rheumatol Int. (2012) 32:323–30. doi: 10.1007/s00296-010-1616-x
80.
Knight JM, Costanzo ES, Singh S, Yin Z, Szabo A, Pawar DS, et al.
The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill. Transl Psychiatry. (2021) 11:58. doi: 10.1038/s41398-020-01164-y
81.
Nascimento FP, Macedo-Júnior SJ, Borges FR, Cremonese RP, da Silva MD, Luiz-Cerutti M, et al.
Thalidomide reduces mechanical hyperalgesia and depressive-like behavior induced by peripheral nerve crush in mice. Neuroscience. (2015) 303:51–8. doi: 10.1016/j.neuroscience.2015.06.044
82.
Fries GR, Saldana VA, Finnstein J, Rein T.
Molecular pathways of major depressive disorder converge on the synapse. Mol Psychiatry. (2023) 28:284–97. doi: 10.1038/s41380-022-01806-1
83.
Soda T, Pasqua T, De Sarro G, Moccia F.
Cognitive impairment and synaptic dysfunction in cardiovascular disorders: The new frontiers of the heart-brain axis. Biomedicines. (2024) 12:2387. doi: 10.3390/biomedicines12102387
84.
Zeng J, Xie Z, Chen L, Peng X, Luan F, Hu J, et al.
Rosmarinic acid alleviate CORT-induced depressive-like behavior by promoting neurogenesis and regulating BDNF/TrkB/PI3K signaling axis. BioMed Pharmacother. (2024) 170:115994. doi: 10.1016/j.biopha.2023.115994
85.
Zhang ZY, Liu YF, Zhang SJ, Zhang PP, Shen XX, Lan JL, et al.
Rescue of CUMS-induced HPA axis hyperfunction and hypothalamic synaptic deficits by Citrus aurantium L. cv. Daidai essential oil via the cAMP/PKA/Grin2b pathway. J Ethnopharmacol. (2025) 343:119423. doi: 10.1016/j.jep.2025.119423
86.
Gouws JM, Sherrington A, Zheng S, Kim JS, Iremonger KJ.
Regulation of corticotropin-releasing hormone neuronal network activity by noradrenergic stress signals. J Physiol. (2022) 600:4347–59. doi: 10.1113/JP283328
87.
Amitai Y.
Thalamocortical synaptic connections: Efficacy, modulation, inhibition and plasticity. Rev Neurosci. (2001) 12:159–73. doi: 10.1515/REVNEURO.2001.12.2.159
88.
Patton MH, Thomas KT, Bayazitov IT, Newman KD, Kurtz NB, Robinson CG, et al.
Synaptic plasticity in human thalamocortical assembloids. Cell Rep. (2024) 43:114503. doi: 10.1016/j.celrep.2024.114503
89.
Brodt S, Inostroza M, Niethard N, Born J.
Sleep—A brain-state serving systems memory consolidation. Neuron. (2023) 111:1050–75. doi: 10.1016/j.neuron.2023.03.005
90.
Kincheski GC, Valentim IS, Clarke JR, Cozachenco D, Castelo-Branco MTL, Ramos-Lobo AM, et al.
Chronic sleep restriction promotes brain inflammation and synapse loss, and potentiates memory impairment induced by amyloid-β oligomers in mice. Brain Behav Immun. (2017) 64:140–51. doi: 10.1016/j.bbi.2017.04.007
91.
Zhao M, Ren Z, Zhao A, Tang Y, Kuang J, Li M, et al.
Gut bacteria-driven homovanillic acid alleviates depression by modulating synaptic integrity. Cell Metab. (2024) 36:1000–1012.e6. doi: 10.1016/j.cmet.2024.03.010
92.
Mishra SK, Hidau MK, Rai S.
Memantine treatment exerts an antidepressant-like effect by preventing hippocampal mitochondrial dysfunction and memory impairment via upregulation of CREB/BDNF signaling in the rat model of chronic unpredictable stress-induced depression. Neurochem Int. (2021) 142:104932. doi: 10.1016/j.neuint.2020.104932
93.
Du J, Diao H, Xu Y, Li X, Yuan C, Nie L, et al.
Astrocytic modulation of GABA transmission in the VTA limits progression of anxiety- and depression-like behaviors in adult mice. Cell Rep. (2025) 44:115824. doi: 10.1016/j.celrep.2025.115824
94.
Deng D, Cui Y, Gan S, Xie Z, Cui S, Cao K, et al.
Sinisan alleviates depression-like behaviors by regulating mitochondrial function and synaptic plasticity in maternal separation rats. Phytomedicine. (2022) 106:154395. doi: 10.1016/j.phymed.2022.154395
95.
Liang X, Tang J, Qi YQ, Luo YM, Yang CM, Dou XY, et al.
Exercise more efficiently regulates the maturation of newborn neurons and synaptic plasticity than fluoxetine in a CUS-induced depression mouse model. Exp Neurol. (2022) 354:114103. doi: 10.1016/j.expneurol.2022.114103
96.
Cui X, Xu Y, Zhu H, Wang L, Zhou J.
Long noncoding RNA NONHSAG045500 regulates serotonin transporter to ameliorate depressive-like behavior via the cAMP-PKA-CREB signaling pathway in a model of perinatal depression. J Matern Fetal Neonatal Med. (2023) 36:2183468. doi: 10.1080/14767058.2023.2183468
97.
Liu HT, Lin YN, Tsai MC, Wu YC, Lee MC.
Baicalein exerts therapeutic effects against endotoxin-induced depression-like behavior in mice by decreasing inflammatory cytokines and increasing brain-derived neurotrophic factor levels. Antioxidants (Basel). (2022) 11:947. doi: 10.3390/antiox11050947
98.
Gim GT, Kim HM, Kim J, Kim J, Whang WW, Cho SH.
Antioxidant effect of Tianwang Buxin pills, a traditional Chinese medicine formula: Double-blind, randomized controlled trial. Am J Chin Med. (2009) 37:227–39. doi: 10.1142/S0192415X09006795
99.
Kunugi H.
Depression and lifestyle: Focusing on nutrition, exercise, and their possible relevance to molecular mechanisms. Psychiatry Clin Neurosci. (2023) 77:420–33. doi: 10.1111/pcn.13551
100.
Zhang K, Liu R, Gao Y, Ma W, Shen W.
Electroacupuncture relieves LPS-induced depression-like behaviour in rats through IDO-mediated tryptophan-degrading pathway. Neuropsychiatr Dis Treat. (2020) 16:2257–66. doi: 10.2147/NDT.S274778
101.
Yeung A, Mischoulon D.
Effects of electroacupuncture for depression-related insomnia. JAMA Netw Open. (2022) 5:e2220573. doi: 10.1001/jamanetworkopen.2022.20573
102.
Yildiz A, Siafis S, Mavridis D, Vieta E, Leucht S.
Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: A systematic review and network meta-analysis. Lancet Psychiatry. (2023) 10:693–705. doi: 10.1016/S2215-0366(23)00199-2
103.
Bonilla-Jaime H, Sánchez-Salcedo JA, Estevez-Cabrera MM, Molina-Jiménez T, Cortes-Altamirano JL, Alfaro-Rodríguez A.
Depression and pain: Use of antidepressants. Curr Neuropharmacol. (2022) 20:384–402. doi: 10.2174/1570159X19666210609161447
104.
Kovich H, Kim W, Quaste AM.
Pharmacologic treatment of depression. Am Fam Physician. (2023) 107:173–81.
105.
Wang Y, Zhou J, Ye J, Sun Z, He Y, Zhao Y, et al.
Multi-omics reveal microbial determinants impacting the treatment outcome of antidepressants in major depressive disorder. Microbiome. (2023) 11:195. doi: 10.1186/s40168-023-01635-6
106.
Irwin MR, Carrillo C, Sadeghi N, Bjurstrom MF, Breen EC, Olmstead R.
Prevention of incident and recurrent major depression in older adults with insomnia: A randomized clinical trial. JAMA Psychiatry. (2022) 79:33–41. doi: 10.1001/jamapsychiatry.2021.3422
107.
Chrysafi M, Jacovides C, Papadopoulou SK, Psara E, Vorvolakos T, Antonopoulou M, et al.
The potential effects of the ketogenic diet in the prevention and co-treatment of stress, anxiety, depression, schizophrenia, and bipolar disorder: From the basic research to the clinical practice. Nutrients. (2024) 16:1546. doi: 10.3390/nu16111546
108.
DelBello MP, Findling RL, Huss M, Necking O, Petersen ML, Schmidt SN, et al.
Vortioxetine in children and adolescents with major depressive disorder: 6-month and 18-month open-label, flexible-dose, long-term extension studies. Eur Child Adolesc Psychiatry. (2025) 34:1425–34. doi: 10.1007/s00787-024-02560-1
109.
Seidman AJ, George CJ, Kovacs M.
Ecological momentary assessment of affect in depression-prone and control samples: Survey compliance and affective yield. J Affect Disord. (2022) 311:63–8. doi: 10.1016/j.jad.2022.05.015
110.
Hetrick SE, McKenzie JE, Bailey AP, Sharma V, Moller CI, Badcock PB, et al.
New generation antidepressants for depression in children and adolescents: A network meta-analysis. Cochrane Database Syst Rev. (2021) 5:CD013674. doi: 10.1002/14651858.CD013674.pub2
111.
Efthimiou O, Taipale H, Radua J, Schneider-Thoma J, Pinzón-Espinosa J, Ortuño M, et al.
Efficacy and effectiveness of antipsychotics in schizophrenia: Network meta-analyses combining evidence from randomised controlled trials and real-world data. Lancet Psychiatry. (2024) 11:102–11. doi: 10.1016/S2215-0366(23)00366-8
112.
Andersen BL, Lacchetti C, Ashing K, Berek JS, Berman BS, Bolte S, et al.
Management of anxiety and depression in adult survivors of cancer: ASCO guideline update. J Clin Oncol. (2023) 41:3426–53. doi: 10.1200/JCO.23.00293
113.
Yarwood B, Taylor R, Angelakis I.
User experiences of CBT for anxiety and depression: A qualitative systematic review and meta-synthesis. Community Ment Health J. (2024) 60:662–71. doi: 10.1007/s10597-023-01196-w
114.
Olthuis JV, Watt MC, Bailey K, Hayden JA, Stewart SH.
Therapist-supported Internet cognitive behavioural therapy for anxiety disorders in adults. Cochrane Database Syst Rev. (2016) 3:CD011565. doi: 10.1002/14651858.CD011565.pub2
115.
Schuffelen J, Maurer LF, Gieselmann A.
Digital CBT-I in comorbid insomnia and depression: Clinical outcomes from a pragmatic randomized controlled trial. Depress Anxiety. (2025) 2025:2171041. doi: 10.1155/da/2171041
116.
Bruijniks SJE, Meeter M, Lemmens L, Peeters F, Cuijpers P, Huibers MJH.
Temporal and specific pathways of change in cognitive behavioral therapy (CBT) and interpersonal psychotherapy (IPT) for depression. Behav Res Ther. (2022) 151:104010. doi: 10.1016/j.brat.2021.104010
117.
Tian P, Chen Y, Zhu H, Wang L, Qian X, Zou R, et al.
Bifidobacterium breve CCFM1025 attenuates major depression disorder via regulating gut microbiome and tryptophan metabolism: A randomized clinical trial. Brain Behav Immun. (2022) 100:233–41. doi: 10.1016/j.bbi.2021.11.023
118.
Lee H, Kim H, Chang YB, Han K, Choi HS, Han SH, et al.
Lactobacillus brevis M2-fermented whey protein hydrolysate increases slow-wave sleep via GABA(A) receptors in rodent models. Foods. (2024) 13:2049. doi: 10.3390/foods13132049
119.
Lin A, Shih CT, Chu HF, Chen CW, Cheng YT, Wu CC, et al.
Lactobacillus fermentum PS150 promotes non-rapid eye movement sleep in the first night effect of mice. Sci Rep. (2021) 11:16313. doi: 10.1038/s41598-021-95659-3
120.
Lin H, Guo Q, Wen Z, Tan S, Chen J, Lin L, et al.
The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors. Microb Cell Fact. (2021) 20:233. doi: 10.1186/s12934-021-01720-1
121.
Lan Y, Lu J, Qiao G, Mao X, Zhao J, Wang G, et al.
Bifidobacterium breve CCFM1025 improves sleep quality via regulating the activity of the HPA axis: A randomized clinical trial. Nutrients. (2023) 15:4700. doi: 10.3390/nu15214700
122.
Mazziotta C, Tognon M, Martini F, Torreggiani E, Rotondo JC.
Probiotics mechanism of action on immune cells and beneficial effects on human health. Cells. (2023) 12:184. doi: 10.3390/cells12010184
123.
Tan Q, Orsso CE, Deehan EC, Kung JY, Tun HM, Wine E, et al.
Probiotics, prebiotics, synbiotics, and fecal microbiota transplantation in the treatment of behavioral symptoms of autism spectrum disorder: A systematic review. Autism Res. (2021) 14:1820–36. doi: 10.1002/aur.2560
124.
Fatimi HE, El-Mansoury B, Tinakoua A, Ndayambaje M, Zaid Y, Khalki H, et al.
Gut microbiota in anxiety and depression: Mechanisms, drug interactions, and therapeutic implications. Pharmacol Rep. (2025) 77:1446–67. doi: 10.1007/s43440-025-00759-w
125.
Aguilera M, Cerdà-Cuéllar M, Martínez V.
Antibiotic-induced dysbiosis alters host-bacterial interactions and leads to colonic sensory and motor changes in mice. Gut Microbes. (2015) 6:10–23. doi: 10.4161/19490976.2014.990790
126.
Mysonhimer AR, Cannavale CN, Bailey MA, Khan NA, Holscher HD.
Prebiotic consumption alters microbiota but not biological markers of stress and inflammation or mental health symptoms in healthy adults: A randomized, controlled, crossover trial. J Nutr. (2023) 153:1283–96. doi: 10.1016/j.tjnut.2023.02.015
127.
Moludi J, Khedmatgozar H, Nachvak SM, Abdollahzad H, Moradinazar M, Sadeghpour Tabaei A.
The effects of co-administration of probiotics and prebiotics on chronic inflammation, and depression symptoms in patients with coronary artery diseases: A randomized clinical trial. Nutr Neurosci. (2022) 25:1659–68. doi: 10.1080/1028415X.2021.1889451
128.
Li P, Yang L, Shao X, Zou Z, Shi H, Sun Y, et al.
Lactobacillales derived from traditional Xizang dairy products improve insomnia and restore neurotransmitter-metabolic profiles via gut microbiota in PCPA-induced mice. Microbiol Res. (2025) 300:128276. doi: 10.1016/j.micres.2025.128276
129.
Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, et al.
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci USA. (2011) 108:16050–5. doi: 10.1073/pnas.1102999108
130.
Pinto-Sanchez MI, Hall GB, Ghajar K, Nardelli A, Bolino C, Lau JT, et al.
Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: A pilot study in patients with irritable bowel syndrome. Gastroenterology. (2017) 153:448–459.e8. doi: 10.1053/j.gastro.2017.05.003
131.
Ma J, Wang J, Wang G, Wan Y, Li N, Luo L, et al.
The potential beneficial effects of Lactobacillus plantarum GM11 on rats with chronic unpredictable mild stress-induced depression. Nutr Neurosci. (2024) 27:413–24. doi: 10.1080/1028415X.2023.2205742
132.
Zhou YM, Yuan JJ, Xu YQ, Gou YH, Zhu YYX, Chen C, et al.
Fecal microbiota as a predictor of acupuncture responses in patients with postpartum depressive disorder. Front Cell Infect Microbiol. (2023) 13:1228940. doi: 10.3389/fcimb.2023.1228940
133.
Dong F, Perdew GH.
The aryl hydrocarbon receptor as a mediator of host-microbiota interplay. Gut Microbes. (2020) 12:1859812. doi: 10.1080/19490976.2020.1859812
134.
Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, et al.
A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. (2014) 63:1275–83. doi: 10.1136/gutjnl-2013-304833
135.
Zheng T, Hao H, Liu Q, Li J, Yao Y, Liu Y, et al.
Effect of extracelluar vesicles derived from Akkermansia muciniphila on intestinal barrier in colitis mice. Nutrients. (2023) 15:4722. doi: 10.3390/nu15224722
136.
Shen Y, Gong Z, Zhang S, Cao J, Mao W, Yao Y, et al.
Besides TLR2 and TLR4, NLRP3 is also involved in regulating Escherichia coli infection-induced inflammatory responses in mice. Int Immunopharmacol. (2023) 121:110556. doi: 10.1016/j.intimp.2023.110556
137.
Sanders ME, Merenstein DJ, Reid G, Gibson GR, Rastall RA.
Probiotics and prebiotics in intestinal health and disease: From biology to the clinic. Nat Rev Gastroenterol Hepatol. (2019) 16:605–16. doi: 10.1038/s41575-019-0173-3
138.
Ma C, Yuan D, Renaud SJ, Zhou T, Yang F, Liou Y, et al.
Chaihu-shugan-san alleviates depression-like behavior in mice exposed to chronic unpredictable stress by altering the gut microbiota and levels of the bile acids hyocholic acid and 7-ketoDCA. Front Pharmacol. (2022) 13:1040591. doi: 10.3389/fphar.2022.1040591
139.
Lu H, Xu X, Fu D, Gu Y, Fan R, Yi H, et al.
Butyrate-producing Eubacterium rectale suppresses lymphomagenesis by alleviating the TNF-induced TLR4/MyD88/NF-κB axis. Cell Host Microbe. (2022) 30:1139–1150.e7. doi: 10.1016/j.chom.2022.07.003
140.
Mei J, Wang Y, Song X, Xie XH, Wang G, Chen C, et al.
The needle in the haystack: Identifying and validating common genes of depression, insomnia, and inflammation. J Affect Disord. (2023) 342:45–53. doi: 10.1016/j.jad.2023.08.127
141.
Tang Y, Wang H, Nie K, Gao Y, Su H, Wang Z, et al.
Traditional herbal formula Jiao-tai-wan improves chronic restrain stress-induced depression-like behaviors in mice. BioMed Pharmacother. (2022) 153:113284. doi: 10.1016/j.biopha.2022.113284
142.
Tao SH, Ren XQ, Zhang LJ, Liu MY.
Association between common cardiovascular drugs and depression. Chin Med J (Engl). (2021) 134:2656–65. doi: 10.1097/CM9.0000000000001875
143.
Xu D, Xu Y, Gao X, Yan M, Zhang C, Wu X, et al.
Potential value of interleukin-6 as a diagnostic biomarker in human MDD and the antidepressant effect of its receptor antagonist tocilizumab in lipopolysaccharide-challenged rats. Int Immunopharmacol. (2023) 124:110903. doi: 10.1016/j.intimp.2023.110903
144.
Mansur RB, Subramaniapillai M, Lee Y, Pan Z, Carmona NE, Shekotikhina M, et al.
Effects of infliximab on brain neurochemistry of adults with bipolar depression. J Affect Disord. (2021) 281:61–6. doi: 10.1016/j.jad.2020.11.128
145.
Fang Y, Ding X, Zhang Y, Cai L, Ge Y, Ma K, et al.
Fluoxetine inhibited the activation of A1 reactive astrocyte in a mouse model of major depressive disorder through astrocytic 5-HT(2B)R/β-arrestin2 pathway. J Neuroinflamm. (2022) 19:23. doi: 10.1186/s12974-022-02389-y
146.
Zhang C, Zhang YP, Li YY, Liu BP, Wang HY, Li KW, et al.
Minocycline ameliorates depressive behaviors and neuro-immune dysfunction induced by chronic unpredictable mild stress in the rat. Behav Brain Res. (2019) 356:348–57. doi: 10.1016/j.bbr.2018.07.001
147.
Song MT, Ruan J, Zhang RY, Deng J, Ma ZQ, Ma SP.
Astragaloside IV ameliorates neuroinflammation-induced depressive-like behaviors in mice via the PPARγ/NF-κB/NLRP3 inflammasome axis. Acta Pharmacol Sin. (2018) 39:1559–70. doi: 10.1038/aps.2017.208
148.
Guo LT, Wang SQ, Su J, Xu LX, Ji ZY, Zhang RY, et al.
Baicalin ameliorates neuroinflammation-induced depressive-like behavior through inhibition of toll-like receptor 4 expression via the PI3K/AKT/FoxO1 pathway. J Neuroinflamm. (2019) 16:95. doi: 10.1186/s12974-019-1474-8
149.
Dong SQ, Zhang QP, Zhu JX, Chen M, Li CF, Liu Q, et al.
Gypenosides reverses depressive behavior via inhibiting hippocampal neuroinflammation. BioMed Pharmacother. (2018) 106:1153–60. doi: 10.1016/j.biopha.2018.07.040
150.
Chen H, Ma Y, Chen M, Chen J, Chen J.
Safflower extract improves depression in mice by inhibiting the TLR4-NLRP3 inflammation signaling pathway. Ann Palliat Med. (2021) 10:8015–23. doi: 10.21037/apm-21-1728
151.
Ma M, Ren Q, Zhang JC, Hashimoto K.
Effects of brilliant blue G on serum tumor necrosis factor-α levels and depression-like behavior in mice after lipopolysaccharide administration. Clin Psychopharmacol Neurosci. (2014) 12:31–6. doi: 10.9758/cpn.2014.12.1.31
152.
Taniguti EH, Ferreira YS, Stupp IJV, Fraga-Junior EB, Mendonça CB, Rossi FL, et al.
Neuroprotective effect of melatonin against lipopolysaccharide-induced depressive-like behavior in mice. Physiol Behav. (2018) 188:270–5. doi: 10.1016/j.physbeh.2018.02.034
153.
Zhuang W, Liu SL, Xi SY, Feng YN, Wang K, Abduwali T, et al.
Traditional Chinese medicine decoctions and Chinese patent medicines for the treatment of depression: Efficacies and mechanisms. J Ethnopharmacol. (2023) 307:116272. doi: 10.1016/j.jep.2023.116272
154.
Liu X, Liu H, Wu X, Zhao Z, Wang S, Wang H, et al.
Xiaoyaosan against depression through suppressing LPS mediated TLR4/NLRP3 signaling pathway in "microbiota-gut-brain" axis. J Ethnopharmacol. (2024) 335:118683. doi: 10.1016/j.jep.2024.118683
155.
Zhou XD, Yang XJ, Zheng Y, Qin ZS, Sha W, Chen G, et al.
Jie-Yu Pill, a proprietary herbal medicine, ameliorates mood disorder-like behavior and cognitive impairment in estrogen-deprived mice exposed to chronic unpredictable mild stress: Implication for a potential therapy of menopause syndrome. Front Psychiatry. (2020) 11:579995. doi: 10.3389/fpsyt.2020.579995
156.
Liu M, Fan G, Liu H.
Integrated bioinformatics and network pharmacology identifying the mechanisms and molecular targets of Guipi Decoction for treatment of comorbidity with depression and gastrointestinal disorders. Metab Brain Dis. (2024) 39:183–97. doi: 10.1007/s11011-023-01308-1
157.
Zeng J, Wang Z, Zhang X, Zhao A, Qi H, Jiang Y, et al.
Exploring the neuroplasticity hypothesis in depression: The role of traditional Chinese herbal medicine. Phytomedicine. (2025) 143:156927. doi: 10.1016/j.phymed.2025.156927
158.
Wu Z, Yin Y, Liu R, Li X, Sun Y, Yau SY, et al.
A refined formula derived from Jiawei-Xiaoyao pill exerts rapid antidepressant-like effects in LPS-induced depression by reducing neuroinflammation and restoring neuroplasticity signaling. J Ethnopharmacol. (2024) 335:118647. doi: 10.1016/j.jep.2024.118647
159.
Wang Y, Peng M.
Research progress on classical traditional Chinese medicine Jieyu pills in the treatment of depression. Neuropsychiatr Dis Treat. (2020) 16:3023–33. doi: 10.2147/NDT.S282384
160.
Li T, Li X, Zhang J, Yu Z, Gong F, Wang J, et al.
Chemical component analysis of the traditional Chinese medicine Guipi Tang and its effects on major depressive disorder at molecular level. Heliyon. (2022) 8:e12182. doi: 10.1016/j.heliyon.2022.e12182
161.
Tran DNH, Hwang IH, Chen FJ, Tseng YP, Chang CM, Tsai SJ, et al.
Core prescription pattern of Chinese herbal medicine for depressive disorders in Taiwan: A nationwide population-based study. Integr Med Res. (2021) 10:100707. doi: 10.1016/j.imr.2020.100707
162.
Dai G, Liu D, Wang Y, Wang Y, Huang Q, San W, et al.
Integrated serum pharmacochemistry and network pharmacology used to explore potential antidepressant mechanisms of the Kaixin San. BioMed Chromatogr. (2025) 39:e70041. doi: 10.1002/bmc.70041
163.
Zhao Y, Xu D, Wang J, Zhou D, Liu A, Sun Y, et al.
The pharmacological mechanism of chaihu-jia-longgu-muli-tang for treating depression: Integrated meta-analysis and network pharmacology analysis. Front Pharmacol. (2023) 14:1257617. doi: 10.3389/fphar.2023.1257617
164.
Chen F, Chen Z, Cheng Y, Li J, Liao R, Zhao Z, et al.
Meta analysis for insomnia Guizhi Gancao Longgu Muli decoction for insomnia a meta-analysis. Complement Ther Clin Pract. (2022) 47:101550. doi: 10.1016/j.ctcp.2022.101550
165.
Wang SJ, Ye W, Li WY, Tian W, Zhang M, Sun Y, et al.
Effects and mechanisms of Xiaochaihu Tang against liver fibrosis: An integration of network pharmacology, molecular docking and experimental validation. J Ethnopharmacol. (2023) 303:116053. doi: 10.1016/j.jep.2022.116053
166.
Gu S, Mou T, Chen J, Wang J, Zhang Y, Cui M, et al.
Develop a stepwise integrated method to screen biomarkers of Baihe-Dihuang Tang on the treatment of depression in rats applying with composition screened, untargeted, and targeted metabolomics analysis. J Sep Sci. (2022) 45:1656–71. doi: 10.1002/jssc.202100841
Come citare questo studio
Dan Tian, Hu Qi, Zhizhong Luo, Jili Xu, Jie Wu. (2026). From gut dysbiosis to synaptic dysfunction in insomnia-associated depression: immune mechanisms and nutritional interventions.. Frontiers in immunology. DOI: 10.3389/fimmu.2026.1940701
Consulta la pubblicazione originale ↗